SparingVision to buy GAMUT and potential Luxturna eye gene therapy competitorFrench genomic medicines firm SparingVision has agreed to buy GAMUT Therapeutics, a biotech specialising in gene therapies for Share XSparingVision to buy GAMUT and potential Luxturna eye gene therapy competitorhttps://pharmaphorum.com/news/sparingvision-to-buy-gamut-and-potential-luxturna-gene-therapy-competitor/
SparingVision raises €44.5m for retinitis pigmentosa gene therapyFrench biotech SparingVision has raised 44.5 million euros ($52.7 million) to develop its gene therapy for a rare Share XSparingVision raises €44.5m for retinitis pigmentosa gene therapyhttps://pharmaphorum.com/news/sparingvision-raises-44-5-million-euros-for-retinitis-pigmentosa-gene-therapy/
